Mayne Pharma 2025 Half Year Results Media Release
Mayne Pharma’s CEO, Mr Shawn Patrick O’Brien said “We are very pleased with the performance of the Mayne Pharma business in the first half, with robust revenue growth recorded, particularly within our Women’s Health segment.” “Our broad portfolio in Dermatology and Women’s Health leverages our existing commercial infrastructure and strengthens our market presence. Our refined US channel strategy has not only increased margins but importantly, is providing greater patient access.”
0
likes
•
0
questions
•
0
company answers
Ask a question
Your question will be sent privately to Mayne Pharma Group Limited. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Mayne Pharma Group Limited a question about this update.